What's in Abbott Laboratories's pipeline?

Abbott Laboratories has 59 drugs in our index: 18 marketed, 0 filed, 31 in Phase 3, 1 in Phase 2, 9 in Phase 1.

Which companies overlap with Abbott Laboratories's portfolio?

Top competitors by shared drug class: Pfizer, Merck Sharp & Dohme LLC, Bayer, Takeda, AstraZeneca.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/abbott.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Abbott Laboratories — Portfolio Competitive Intelligence Brief

Abbott Laboratories (ABT) pipeline: 18 marketed, 0 filed, 31 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

ABT (NYSE) 18 marketed 0 filed 31 Phase 3 1 Phase 2 9 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Prosom	ESTAZOLAM	marketed	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-2/gamma-2	Neuroscience	1990-01-01
Pentothal	THIOPENTAL	marketed	thiopental	GABA-A receptor alpha-1/beta-2/gamma-2	Neuroscience	1982-01-01
Golytely	Sodium Bicarbonate	marketed	sodium bicarbonate		Gastroenterology	1981-01-01
Calcium Gluceptate	calcium glucoheptonate	marketed	calcium glucoheptonate		Cardiovascular	1972-01-01
trandolapril/verapamil	trandolapril/verapamil	marketed	ACE inhibitor / calcium channel blocker combination	Angiotensin-converting enzyme (ACE); L-type voltage-gated calcium channels	Cardiovascular
Sevoflurane Inhalational Induction and Maintenance	Sevoflurane Inhalational Induction and Maintenance	marketed	Volatile anesthetic agent	GABA receptors, NMDA receptors, potassium channels	Anesthesiology
Lotrel (amlodipine/benazepril)	Lotrel (amlodipine/benazepril)	marketed	Calcium channel blocker / ACE inhibitor combination	L-type calcium channels (amlodipine); Angiotensin-converting enzyme (benazepril)	Cardiovascular
Venocur Triplex®	Venocur Triplex®	marketed
Lopinavir/ritonavir (Kaletra)	Lopinavir/ritonavir (Kaletra)	marketed	HIV protease inhibitor	HIV protease	Infectious Disease
cefdinir (Omnicef)	cefdinir (Omnicef)	marketed	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)	Infectious Disease
Hectorol® injection	Hectorol® injection	marketed
paricalcitol capsule	paricalcitol capsule	marketed	Vitamin D receptor agonist	Vitamin D receptor (VDR)	Nephrology / Endocrinology

Therapeutic area mix

Cardiovascular · 10
Immunology · 7
Gastroenterology · 7
Other · 3
Infectious Disease · 3
Hepatology / Gastroenterology · 2
Nephrology / Endocrinology · 2
Oncology; Endocrinology · 2
Neuroscience · 2
Pain management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 7 shared drug classes
Merck Sharp & Dohme LLC · 7 shared drug classes
Bayer · 4 shared drug classes
Takeda · 4 shared drug classes
AstraZeneca · 3 shared drug classes
National Taiwan University Hospital · 3 shared drug classes
GlaxoSmithKline · 3 shared drug classes
Ahn-Gook Pharmaceuticals Co.,Ltd · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Abbott Laboratories:

Cite this brief

Drug Landscape (2026). Abbott Laboratories — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/abbott. Accessed 2026-05-13.